Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Debt to Equity (2020 - 2024)

Bicycle Therapeutics (BCYC) has disclosed Debt to Equity for 5 consecutive years, with $0.04 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Debt to Equity fell 74.48% year-over-year to $0.04, compared with a TTM value of $0.04 through Jun 2024, down 74.48%, and an annual FY2023 reading of $0.08, down 26.08% over the prior year.
  • Debt to Equity was $0.04 for Q2 2024 at Bicycle Therapeutics, down from $0.09 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.21 in Q2 2021 and bottomed at $0.04 in Q2 2024.
  • Average Debt to Equity over 5 years is $0.12, with a median of $0.11 recorded in 2022.
  • The sharpest move saw Debt to Equity soared 43.21% in 2023, then plummeted 74.48% in 2024.
  • Year by year, Debt to Equity stood at $0.15 in 2020, then tumbled by 43.22% to $0.09 in 2021, then increased by 29.76% to $0.11 in 2022, then decreased by 26.08% to $0.08 in 2023, then plummeted by 57.26% to $0.04 in 2024.
  • Business Quant data shows Debt to Equity for BCYC at $0.04 in Q2 2024, $0.09 in Q1 2024, and $0.08 in Q4 2023.